Black Diamond Therapeutics, Inc.BDTXNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank55
3Y CAGR-8.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-8.0%/yr
vs -41.1%/yr prior
Acceleration
+33.1pp
Accelerating
Percentile
P55
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 12.00% |
| Q3 2025 | -13.66% |
| Q2 2025 | -17.39% |
| Q1 2025 | -16.96% |
| Q4 2024 | 14.61% |
| Q3 2024 | -45.52% |
| Q2 2024 | 42.87% |
| Q1 2024 | 20.39% |
| Q4 2023 | -29.17% |
| Q3 2023 | 14.25% |
| Q2 2023 | 1.03% |
| Q1 2023 | -6.01% |
| Q4 2022 | 15.39% |
| Q3 2022 | -10.05% |
| Q2 2022 | -11.59% |
| Q1 2022 | 23.02% |
| Q4 2021 | -17.08% |
| Q3 2021 | -3.23% |
| Q2 2021 | 1.30% |
| Q1 2021 | 45.44% |
| Q4 2020 | -2.23% |
| Q3 2020 | 14.27% |
| Q2 2020 | -12.07% |
| Q1 2020 | 91.57% |
| Q4 2019 | 14.72% |
| Q3 2019 | 85.81% |
| Q2 2019 | 63.41% |
| Q1 2019 | 24.14% |
| Q4 2018 | -5.79% |
| Q3 2018 | 144.56% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |